Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Phathom Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target Maximize Your Portfolio ...
Phathom spikes as Cantor Fitzgerald bullish on IP claims
Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related ...
Gastroesophageal Reflux Disease Market Predicted To See Upsurge Through 2034, Highlights Delveinsight
Gastroesophageal Reflux disease market Insights. DelveInsight's Gastroesophageal Reflux Disease Market report offers an in-depth understanding of the epide ...
Yahoo Finance5d
Phathom Pharmaceuticals, Inc. (PHAT)
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.